Q-omics provides the consensus-scored MARK2P17 profile across patient tissues and cancer cell-line models. MARK2P17 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MARK2P17 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, MARK2P17 RNA expression shows 6,324 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KIRC, and STAD as cancer lineages where MARK2P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARK2P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARK2P17 survival associations across molecular data types. MARK2P17 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARK2P17 RNA expression–survival associations across cancer types. High MARK2P17 expression shows unfavorable associations in UVM, LIHC, LUSC, THCA, THYM and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MARK2P17 RNA expression.
This table summarizes MARK2P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MARK2P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARK2P17 shows lower tumor expression in THCA and KIRP and higher tumor expression in KIRC, PAAD and STAD. The KIRC box plot shows higher MARK2P17 RNA expression in tumor versus normal tissue (log2 FC = +0.024, t-test p = .007).
This table shows molecular features associated with MARK2P17 in patient tissues and cancer cell lines. In patient samples, MARK2P17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
